ArticleNeoplasia (New York, N.Y.)2025

Therapeutic benefit of the dual ALK/FAK inhibitor ESK440 in ALK-driven neuroblastoma.

Seema Chugh et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.